|
|
Metabolic Syndrome: Pipeline Analysis and U.S. Market ForecastPublished by: CHI Insight Pharma Reports Published: Jan. 1, 2005 - 152 Pages Table of ContentsChapter 1: Introduction 1.1. Metabolic Syndrome: A Multifaceted Syndrome by Many Names 1.2. Etiology of Primary Components: The Vicious Cycle of “Diabesity” 1.3. Further Sequels: Endothelial Dysfunction, Inflammation, and Psychiatric Implications 1.4. The National Institutes of Health ATP III Guidelines and Definition Chapter 2: Epidemiological Aspects 2.1. Overweight/Obesity and Lack of Physical Activity 2.2. Insulin Resistance and Diabetes 2.3. Elevated Blood Pressure and Hypertension 2.4. Dyslipidemia 2.5. Estimates for Prevalence and Incidence of the Metabolic Syndrome Chapter 3: Current Options for Pharmacological Intervention 3.1. Limited Potential for Lifestyle Modifications 3.2. Current Pharmacological Treatment of Component Entities Drugs for Insulin Resistance and Emerging Type 2 Diabetes -Sulphonylureas—Stimulators of Basal Insulin Release -Post-Prandial Insulin Secretion Stimulators—the “Meglitinides” -Insulin Sensitizers --Metformin (Bristol-Myers Squibb’s glucophage/glucamet; generics) -Glitazones—The Original PPAR Agonists --Avandia (rosiglitazone maleate, GlaxoSmithKline) --Actos (pioglitazone HCl, Eli Lilly and Takeda) -Glitazone/Metformin Fixed Combination Products -Alpha-Glucosidase Inhibitors: Intestinally Acting Glucose Retardants Drugs for Dyslipidemia: Fibrates, Statins, and Niacin -Fibrates --Lopid (Pfizer’s gemfibrozil and generics) --TriCor/Lipanthyl/Lipidil (fenofibrate, Abbott Laboratories and Groupe Fournier; generics) --Bezalip (Roche’s bezafibrate) --Lipanor/Modalim (Sanofi-Aventis’ ciprofibrate) -Statins -Cholesterol Absorption Inhibitors --Ezetimibe (Schering-Plough/Merck & Co.’s Zetia) -Niaspan and Advicor Hypertension: Drug Class Differences in the Metabolic Effects Weight Reduction Agents -Xenical (orlistat, Roche) -Meridia/Reductil (sibutramine, Abbott Laboratories) -“Short-Term Slimmers”: No Relevance to the Metabolic Syndrome Chapter 4: Unmet Treatment Need in the Metabolic Syndrome 4.1. Unmet Need in Current Drugs and Treatment Schedules Weight Reduction Drugs Glucose-Lowering Drugs Lipid-Lowering Drugs Anti-Hypertensive Drugs 4.2. Genetic Predisposition and Tailored Therapies: A Great Task Ahead 4.3. Unconventional Approaches: A Role for Neurotrophic Factors? 4.4. Summary 4.5. SWOT Exhibits for the Metabolic Syndrome Component-Disorder Drugs Chapter 5: Improvements Ahead—Breakthroughs on the Horizon? 5.1. Pharmacological Strategies to Support Weight Loss: A Bumpy Road Regeneron’s Axokine: A Nerve Growth Factor Agonist Completing Clinical Development Acomplia (rimonabant) and Other CB1 Receptor Antagonists for Slimming New Pancreatic Lipase Inhibitors in the Pipeline Symlin (Pramlintide acetate, an Analog of Amylin) An Appetite Suppressant from a South African Cactus Targeting the Adrenergic System—Adjusting the Metabolic Rate 5-HT2c Receptor Agonists Neuropeptide Y Receptor Agonists Melanocortin Receptor Agonists 5.2. Potential Treatments for Insulin Resistance and Diabetes Dual PPAR Stimulators—A New Class of Drugs Tailored to Metabolic Syndrome Therapy Dipeptidyl Peptidase Inhibitors—Blocking Degradation of Glucagon- Like Peptide 1 Glucagon-Like Peptide Analogs Sodium-Dependent Glucose Co-Transporter (SGLT) Inhibitors An Antisense PTP-1B Gene Silencer 5.3. New Developments in Lipid Disorders Cholesteryl Ester Transfer Protein (CETP) Inhibitors Ibrolipim: A Lipoprotein Lipase Activator An Antibody Mix for Dyslipidemia Inhibition of Acetyl-CoA Carboxylase Antisense Drugs Omacor, an FDA-Approved Nutritional Supplement 5.4. Targeting Hypertension in the Metabolic Syndrome Renin Inhibitors Selective Aldosterone Blockade Endothelin A Receptor Antagonists 5.5. Potential Improvements in the Therapy of Gout Chapter 6: U.S. Market Forecast for Metabolic Syndrome Component Disorders: 2003-2018 6.1. Introduction 6.2. Methodology and Sources 6.3. United States Market Forecast for Dyslipidemia Market Overview Patent Expirations Drug Launches Epidemiology 6.4. United States Market Forecast for Type 2 Diabetes Market Overview Patent Expirations Drug Launches Epidemiology 6.5. United States Market Forecast for Obesity Market Overview Patent Expirations Drug Launches Epidemiology 6.6. United States Market Forecast for Hypertension Market Overview Patent Expirations Drug Launches Epidemiology Chapter 7: Pipeline and Research Program Profiles 7.1. Sanofi-Aventis 7.2. Eli Lilly 7.3. Novo Nordisk A/S 7.4. Bristol-Myers Squibb 7.5. GlaxoSmithKline 7.6. Roche Group 7.7. Merck & Co. 7.8. DeveloGen AG 7.9. Wellstat Therapeutics Corp. 7.10. Amylin Pharmaceuticals 7.11. Ligand Pharmaceuticals 7.12. Regeneron Pharmaceuticals, Inc. 7.13. Biovitrum AB 7.14. Summary References Glossary Index AbstractMetabolic Syndrome: Pipeline Analysis and U.S. Market Forecast is a thorough evaluation of marketed therapies and drugs in development for obesity, dyslipidemia, type 2 diabetes, and hypertension.Metabolic Syndrome is a cluster of risk factors for atherosclerotic disease and type 2 diabetes mellitus comprising obesity, insulin resistance, hypertension, and dyslipidemia. The eligible treatment population in the U.S. for these four conditions is currently 40 million patients and will nearly double over the next 15 years, bringing unprecedented social and economic impacts.
Specifically, this report:
|
|
|||
|
About MarketResearch.com
|
||||